8-K current report · filed Nov 5, 2026

Xeris Biopharma Holdings, Inc. (XERS) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1XERS overview

Short answer

Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026.

Xeris Biopharma Holdings, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 and nine-month 2026 operating results and business highlights announced for periods ended September 30, 2026
  • Investor-relevant financial details and management commentary contained in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $107.2M, up 44% YoY, led by Recorlev revenue $71.5M, up 93%
  • Gross margin reached 88% versus 85%, while adjusted EBITDA increased to $30.8M from $17.4M
  • Full-year 2026 revenue guidance raised to $395M-$405M, signaling stronger near-term commercial momentum
  • 2030 revenue outlook raised above $1B from approximately $750M, primarily reflecting faster Recorlev expansion
  • 2028 convertible notes fully retired, eliminating approximately $34M debt and $3M annual interest expense

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Xeris Biopharma Holdings, Inc. 8-K filings

Get the next XERS 8-K as it lands

Follow XERS for push alerts, or ask the research agent what this filing means.